{"protocolSection":{"identificationModule":{"nctId":"NCT01077713","orgStudyIdInfo":{"id":"ML21868"},"secondaryIdInfos":[{"id":"2008-008739-27"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer","officialTitle":"Randomised Phase II Trial of Bevacizumab (AVASTINÂ®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES"},"statusModule":{"statusVerifiedDate":"2015-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-02"},"primaryCompletionDateStruct":{"date":"2014-07","type":"ACTUAL"},"completionDateStruct":{"date":"2014-07","type":"ACTUAL"},"studyFirstSubmitDate":"2010-02-09","studyFirstSubmitQcDate":"2010-02-26","studyFirstPostDateStruct":{"date":"2010-03-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-09-09","resultsFirstSubmitQcDate":"2015-09-09","resultsFirstPostDateStruct":{"date":"2015-10-08","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-09-09","lastUpdatePostDateStruct":{"date":"2015-10-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This 2 arm study will evaluate the efficacy and safety of Avastin + gemcitabine, and Avastin + gemcitabine + attenuated doses of cisplatin, as first line treatment in elderly patients with non-squamous non-small cell lung cancer. Patients will be randomised to receive either Avastin 7.5mg/kg iv on day 1 + gemcitabine 1200mg/m2 on days 1-8 of each 3 week cycle, or Avastin 7.5mg/kg iv on day 1 + cisplatin 60mg/m2 on day 1 + gemcitabine 1000mg/m2 on days 1-8 of each 3 week cycle. After 6 cycles of combination therapy, all patients will continue to receive Avastin monotherapy. The anticipated time on study treatment is until disease progression, and the target sample size is \\<100 individuals."},"conditionsModule":{"conditions":["Non-Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":86,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: gemcitabine"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: cisplatin","Drug: gemcitabine"]}],"interventions":[{"type":"DRUG","name":"bevacizumab [Avastin]","description":"7.5mg/kg iv on day 1 of each 3 week cycle","armGroupLabels":["1","2"]},{"type":"DRUG","name":"cisplatin","description":"60mg/m2 on day 1 of each 3 week cycle","armGroupLabels":["2"]},{"type":"DRUG","name":"gemcitabine","description":"1200mg/m2 on days 1-8 of each 3 week cycle","armGroupLabels":["1"]},{"type":"DRUG","name":"gemcitabine","description":"1000mg/m2 on days 1-8 of each 3 week cycle","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Alive and Without Progressive Disease at Month 6","description":"Disease progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (v 1.1). Disease progression was defined at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Month 6"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Disease Progression or Death","description":"Disease progression was assessed according to RECIST criteria v1.1. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)"},{"measure":"Progression Free Survival (PFS)","description":"PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Disease progression was assessed according to RECIST criteria v 1.1. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)"},{"measure":"Percentage of Participants Alive at 12 Months After Randomization","timeFrame":"1 year"},{"measure":"Percentage of Participants Who Died","timeFrame":"From randomization to death or end of the study (up to 53 months)"},{"measure":"Overall Survival (OS)","description":"OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.","timeFrame":"From randomization to death or end of the study (up to 53 months)"},{"measure":"Percentage of Participants by Best Overall Response","description":"Best overall response was defined as the best response recorded from the start of the treatment until disease progression/recurrence, assessed according to RECIST criteria v 1.1. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to less than (\\<) 10 millimeter (mm) in short axis; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions; Progressive Disease (PD): at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)"},{"measure":"Percentage of Participants With an Objective Response","description":"Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \\<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.","timeFrame":"Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6"},{"measure":"Percentage of Participants With Disease Control","description":"Disease control was defined as having CR/PR/SD as per RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \\<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6"},{"measure":"Duration of Response (DoR)","description":"DoR was defined for participants who had achieved an objective response (CR/PR) (whichever status was recorded first) as the time period from first documentation of a response to the date of first occurrence of investigator documented disease progression or death. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \\<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as increase by at least 20% in the sum of the longest diameters of each target lesion, taking as a reference the smallest sum of the longest diameters or appearance of one or more new lesions. DoR was estimated using Kaplan Meier method.","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=70 years of age;\n* inoperable, locally advanced, metastatic non-squamous non-small cell lung cancer;\n* \\>=1 measurable lesion;\n* ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment;\n* radical radiotherapy with curative intent within 28 days prior to enrollment;\n* history of \\>=grade 2 hemoptysis in 3 months prior to enrollment;\n* evidence of CNS metastases;\n* current or recent (within 10 days of first dose of Avastin)use of aspirin (\\>325 mg/day)or full dose anticoagulants or thrombolytic agents for therapeutic purposes.","healthyVolunteers":false,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Rionero in Vulture","state":"Basilicate","zip":"85028","country":"Italy","geoPoint":{"lat":40.92328,"lon":15.6711}},{"city":"Catanzaro","state":"Calabria","zip":"88100","country":"Italy","geoPoint":{"lat":38.88247,"lon":16.60086}},{"city":"Avellino","state":"Campania","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"city":"Bologna","state":"Emilia-Romagna","zip":"40139","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"city":"Aviano","state":"Friuli Venezia Giulia","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"city":"Udine","state":"Friuli Venezia Giulia","zip":"33100","country":"Italy","geoPoint":{"lat":46.0693,"lon":13.23715}},{"city":"Rome","state":"Lazio","zip":"00128","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Rome","state":"Lazio","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Rome","state":"Lazio","zip":"00189","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Viterbo","state":"Lazio","zip":"01100","country":"Italy","geoPoint":{"lat":42.41937,"lon":12.1056}},{"city":"Genoa","state":"Liguria","zip":"16149","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94439}},{"city":"Bergamo","state":"Lombardy","zip":"24128","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"city":"Milan","state":"Lombardy","zip":"20142","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"city":"Monza","state":"Lombardy","zip":"20052","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"city":"Rho","state":"Lombardy","zip":"20017","country":"Italy","geoPoint":{"lat":45.53245,"lon":9.0402}},{"city":"Sondalo","state":"Lombardy","zip":"23039","country":"Italy","geoPoint":{"lat":46.32983,"lon":10.3269}},{"city":"Sondrio","state":"Lombardy","zip":"23100","country":"Italy","geoPoint":{"lat":46.16852,"lon":9.87134}},{"city":"Novara","state":"Piedmont","zip":"28100","country":"Italy","geoPoint":{"lat":45.44694,"lon":8.62118}},{"city":"Catania","state":"Sicily","zip":"95100","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"city":"Ancona","state":"The Marches","zip":"60121","country":"Italy","geoPoint":{"lat":43.60717,"lon":13.5103}},{"city":"Pesaro","state":"The Marches","zip":"61122","country":"Italy","geoPoint":{"lat":43.90921,"lon":12.9164}},{"city":"Lido di Camaiore","state":"Tuscany","zip":"55043","country":"Italy","geoPoint":{"lat":43.90012,"lon":10.2269}},{"city":"Perugia","state":"Umbria","zip":"06156","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"city":"Mirano","state":"Veneto","zip":"30035","country":"Italy","geoPoint":{"lat":45.49458,"lon":12.10775}},{"city":"Padua","state":"Veneto","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 and gemcitabine 1200 milligrams per square meter (mg/m\\^2) IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"FG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"42"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"36"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Progressive Disease (PD)","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"29"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants randomized set (RND) included all participants who provided informed consent and who were randomized to study medication.","groups":[{"id":"BG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"BG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"86"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"74.2","spread":"3.2"},{"groupId":"BG001","value":"73.8","spread":"3.5"},{"groupId":"BG002","value":"74.0","spread":"3.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"28"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"58"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Alive and Without Progressive Disease at Month 6","description":"Disease progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (v 1.1). Disease progression was defined at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), progression of existing non-target lesions, or presence of new lesions.","populationDescription":"Intent-to-treat (ITT) set included all participants in the RND set who received at least one dose of any study medication; participants were classified according to treatment received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 6","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","lowerLimit":"12.5","upperLimit":"38.6"},{"groupId":"OG001","value":"30.0","lowerLimit":"15.8","upperLimit":"44.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Progression or Death","description":"Disease progression was assessed according to RECIST criteria v1.1. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.0"},{"groupId":"OG001","value":"90.0"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Disease progression was assessed according to RECIST criteria v 1.1. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.33","lowerLimit":"2.20","upperLimit":"5.97"},{"groupId":"OG001","value":"6.82","lowerLimit":"4.49","upperLimit":"8.52"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Alive at 12 Months After Randomization","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 year","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.2","lowerLimit":"22.8","upperLimit":"51.7"},{"groupId":"OG001","value":"47.5","lowerLimit":"32.0","upperLimit":"63.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From randomization to death or end of the study (up to 53 months)","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8"},{"groupId":"OG001","value":"72.5"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization to death or end of the study (up to 53 months)","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.66","lowerLimit":"3.38","upperLimit":"13.0"},{"groupId":"OG001","value":"12.0","lowerLimit":"9.93","upperLimit":"19.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Best Overall Response","description":"Best overall response was defined as the best response recorded from the start of the treatment until disease progression/recurrence, assessed according to RECIST criteria v 1.1. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to less than (\\<) 10 millimeter (mm) in short axis; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions; Progressive Disease (PD): at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"CR","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"}]}]},{"title":"PR","categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"3.6","upperLimit":"24.3"},{"groupId":"OG001","value":"35.0","lowerLimit":"20.2","upperLimit":"49.8"}]}]},{"title":"SD","categories":[{"measurements":[{"groupId":"OG000","value":"39.5","lowerLimit":"24.9","upperLimit":"54.1"},{"groupId":"OG001","value":"37.5","lowerLimit":"22.5","upperLimit":"52.5"}]}]},{"title":"PD","categories":[{"measurements":[{"groupId":"OG000","value":"16.3","lowerLimit":"5.2","upperLimit":"27.3"},{"groupId":"OG001","value":"12.5","lowerLimit":"2.2","upperLimit":"22.7"}]}]},{"title":"Not Assessable","categories":[{"measurements":[{"groupId":"OG000","value":"30.2","lowerLimit":"16.5","upperLimit":"44.0"},{"groupId":"OG001","value":"15.0","lowerLimit":"3.9","upperLimit":"26.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Objective Response","description":"Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \\<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Cycle 3","categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"2.05","upperLimit":"21.2"},{"groupId":"OG001","value":"27.5","lowerLimit":"13.7","upperLimit":"41.3"}]}]},{"title":"Cycle 6","categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"0.62","upperLimit":"18.0"},{"groupId":"OG001","value":"15.0","lowerLimit":"3.93","upperLimit":"26.1"}]}]},{"title":"Month 6","categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"0.00","upperLimit":"10.9"},{"groupId":"OG001","value":"10.0","lowerLimit":"0.70","upperLimit":"19.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control","description":"Disease control was defined as having CR/PR/SD as per RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \\<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","populationDescription":"ITT set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Cycle 3","categories":[{"measurements":[{"groupId":"OG000","value":"53.5","lowerLimit":"38.6","upperLimit":"68.4"},{"groupId":"OG001","value":"67.5","lowerLimit":"53.0","upperLimit":"82.0"}]}]},{"title":"Cycle 6","categories":[{"measurements":[{"groupId":"OG000","value":"27.9","lowerLimit":"14.5","upperLimit":"41.3"},{"groupId":"OG001","value":"37.5","lowerLimit":"22.5","upperLimit":"52.5"}]}]},{"title":"Month 6","categories":[{"measurements":[{"groupId":"OG000","value":"25.6","lowerLimit":"12.5","upperLimit":"38.6"},{"groupId":"OG001","value":"30.0","lowerLimit":"15.8","upperLimit":"44.2"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR was defined for participants who had achieved an objective response (CR/PR) (whichever status was recorded first) as the time period from first documentation of a response to the date of first occurrence of investigator documented disease progression or death. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \\<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as increase by at least 20% in the sum of the longest diameters of each target lesion, taking as a reference the smallest sum of the longest diameters or appearance of one or more new lesions. DoR was estimated using Kaplan Meier method.","populationDescription":"ITT set.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)","groups":[{"id":"OG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity."},{"id":"OG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.23","lowerLimit":"3.93","upperLimit":"NA","comment":"It was not possible to estimate the statistic using Kaplan-Meier because upper bound of 95% confidence interval was not reached."},{"groupId":"OG001","value":"5.97","lowerLimit":"2.20","upperLimit":"9.08"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From baseline to 28 days after last dose of any study drug (up to 54 months)","description":"Safety set included all participants in the RND set who received at least one dose of any study medication. Participants were classified according to treatment received.","eventGroups":[{"id":"EG000","title":"Bevacizumab + Gemcitabine","description":"Participants received bevacizumab 7.5 mg/kg IV infusion on Day 1 and gemcitabine 1200 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21-day cycle until progressive disease, death, or intolerable toxicity.","seriousNumAffected":17,"seriousNumAtRisk":43,"otherNumAffected":38,"otherNumAtRisk":43},{"id":"EG001","title":"Bevacizumab + Gemcitabine + Cisplatin","description":"Participants received bevacizumab 7.5 mg/kg IV infusion and cisplatin 60 mg/m\\^2 IV infusion on Day 1 and gemcitabine 1000 mg/m\\^2 IV infusion on Days 1 and 8 of each 21-day cycle for a maximum of 6 cycles. After Cycle 6, participants continued treatment with bevacizumab 7.5 mg/kg IV infusion on Day 1 of every 21 day cycle until progressive disease, death, or intolerable toxicity.","seriousNumAffected":10,"seriousNumAtRisk":40,"otherNumAffected":37,"otherNumAtRisk":40}],"seriousEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Pulmonary Haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Hospitalisation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":1,"numAtRisk":40}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43},{"groupId":"EG001","numAffected":12,"numAtRisk":40}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":11,"numAtRisk":40}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":43},{"groupId":"EG001","numAffected":23,"numAtRisk":40}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43},{"groupId":"EG001","numAffected":16,"numAtRisk":40}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43},{"groupId":"EG001","numAffected":8,"numAtRisk":40}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43},{"groupId":"EG001","numAffected":5,"numAtRisk":40}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":43},{"groupId":"EG001","numAffected":17,"numAtRisk":40}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43},{"groupId":"EG001","numAffected":6,"numAtRisk":40}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":43},{"groupId":"EG001","numAffected":10,"numAtRisk":40}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":43},{"groupId":"EG001","numAffected":15,"numAtRisk":40}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":5,"numAtRisk":40}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":43},{"groupId":"EG001","numAffected":8,"numAtRisk":40}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":4,"numAtRisk":40}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43},{"groupId":"EG001","numAffected":5,"numAtRisk":40}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":3,"numAtRisk":40}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":3,"numAtRisk":40}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43},{"groupId":"EG001","numAffected":4,"numAtRisk":40}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43},{"groupId":"EG001","numAffected":8,"numAtRisk":40}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43},{"groupId":"EG001","numAffected":0,"numAtRisk":40}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43},{"groupId":"EG001","numAffected":6,"numAtRisk":40}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43},{"groupId":"EG001","numAffected":7,"numAtRisk":40}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":2,"numAtRisk":40}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43},{"groupId":"EG001","numAffected":4,"numAtRisk":40}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":3,"numAtRisk":40}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":43},{"groupId":"EG001","numAffected":5,"numAtRisk":40}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":43},{"groupId":"EG001","numAffected":9,"numAtRisk":40}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-LaRoche","email":"genentech@druginfo.com","phone":"800 821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D002945","term":"Cisplatin"},{"id":"D000093542","term":"Gemcitabine"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"}]}},"hasResults":true}